IONSSTOCK_USDT
币种名称 IONSSTOCK
流通率 0.00%
交易规则 (IONSUSDT Perpetual)
杠杆倍数 1 ~ 20
最小下单数量 0.5373 USDT
市价单单笔最大下单数量 5,507.325 USDT
限价单单笔最大下单数量 5,507.325 USDT
最小变动价位 0.01
限价订单价格上限/下限比例 10% / 10%
最大挂单数量 50
价差保护阈值 10%
合约面值 1 张 = 0.01 IONS
强平手续费率 0.02%
查看所有合约交易规则基于各类指标等数据计算得到的分析，用于辅助判断买入和卖出信号。
数值指标
| 名称 | 数值 | 操作 |
|---|
| KDJ (9,3,3)_K | | 中立 |
| KDJ (9,3,3)_D | | 中立 |
| KDJ (9,3,3)_J | | 中立 |
| RSI (14) | 100 | 卖出 |
| StochRSI (%K) | 0 | 买入 |
| StochRSI (%D) | 0 | 买入 |
多维度指标
| 名称 | 操作 |
|---|
| KDJ (9,3,3)_K&D | 中立 |
| KDJ (9,3,3) 金叉死叉 | 中立 |
| MACD (12,26,9) 金叉死叉 | 中立 |
| DEA 穿过零轴 | 中立 |
| BOLL (20,2) 超买超卖 | 中立 |
| BOLL (20,2) 中轨金叉死叉 | 中立 |
总结: 卖出 3 · 中立 9 · 买入 14 — 买入
简介
Ionis Pharmaceuticals, Inc. is an industry leader in the invention and development of antisense drugs, utilizing its new drug development platform to develop a large number of best-in-class medicines. Antisense technology opens a bridge between genetics and pharmaceuticals. With its highly efficient and prolific drug development platform, the company can expand its own and its partners' drug portfolios with antisense drugs, meeting a wide range of pharmaceutical needs. The company's strategy is to do what it does best—find unique antisense drugs and develop them into key clinical inflection points. The company invents and conducts early-stage research on new drugs, then licenses them to partners. The company maximizes the value of its drugs by outsourcing late-stage development to leading pharmaceutical companies such as Biogen Idec, Bristol-Myers Squibb, Genzyme, Sanofi, GlaxoSmithKline, and Eli Lilly. Ionis Pharmaceuticals, Inc.'s flagship product, KYNAMRO, is targeting patients with familial hypercholesterolemia. The company was founded in California, USA in 1989.
Disclaimer: Data is collected from third-party platforms, provided for reference only, and does not constitute any form of investment advice or guarantee.
